T Cell Attack: Taking Down Cancer with Immunotherapy

By Julie Grisham,

Tuesday, October 11, 2016

Cell Therapy and Cell Engineering Facility

MSK physician-scientist Prasad Adusumilli is focused on developing more-effective immunotherapy approaches for treating tumors in the chest.

This magnified image shows immune cells, in blue, attacking and killing mesothelioma cells, in magenta. (Cells have been artificially colored.)

The immune cells are specially modified white blood cells called CAR T cells. These cells are filtered from a patient’s blood, engineered to recognize cancer cells, and then returned to the patient’s body. Once infused back into the patient, they seek out and attack cancer cells. (CAR stands for chimeric antigen receptor, which is the part added to the T cell that enables it to recognize the cancer.)

This treatment approach is a type of immunotherapy. It shows promise for treating blood cancers such as leukemia as well as some solid tumors, including certain types of lung cancer, breast cancer, and mesothelioma.

The image is from the lab of physician-scientist Prasad Adusumilli, who is leading immunotherapy research using T cells that are modified to recognize mesothelin — a protein found on the surface of some tumors in the chest — and to attack those cells.

Learn more about Dr. Adusumilli’s research.


Dr-Adusumillil performed my surgery in May 2016. Just had first cat scan and am cancer free. Dr Adusumillil was professional and explained everything in laymans terms to my family and me. I can't stop telling everyone (coworkers and friends) how wonderful Sloan was and would highly recommend your hospital and of course Dr Adusumillil.

Dear Renee, we are glad to know that your surgery went well and that you have felt well-cared for by Dr. Adusumilli and his team. Thank you for sharing your thoughts and experience on our blog.

Are they doing any clinical studies and would this work on Invasive Mammary Carcinoma? Thanks

Hi Sharyce, there are a number of immunotherapy treatments currently being evaluated for breast cancer in clinical trials, but it's too early to say which ones will ultimately be effective. If you're interested in making an appointment to learn more, you can call 800-525-2225 or go to https://www.mskcc.org/experience/become-patient/appointment for more information on making an appointment. Thank you for your comment.

Can Dr.Adusumillil treat ovarian small cell cancers with his immune therapy approach??

Dear Mike, Dr. Adusumilli specializes in cancers in the chest, but we offer a number of clinical trials for people with ovarian cancer. To see a list of our trials evaluating new treatments - including immunotherapies -- for ovarian cancer, please visit https://www.mskcc.org/cancer-care/types/ovarian/clinical-trials. If you have questions about any of these studies or would like to make an appointment for a loved one, please call our Physician Referral Service at 800-525-2225. Thank you for reaching out to us.

How has this method helped Mesothelioma patients? How many treatments are needed? currently being treated at Roswell after having surgery to remove lining of the lung 5 yrs ago, now a few more nodules have surfaced.

Hi Alfred, this treatment is currently under investigation in mesothelioma patients whose cancer expresses a certain gene, called mesothelin. If you're interested in learning about this trial, you can call 800-525-2225 or go to https://www.mskcc.org/experience/become-patient/appointment for more information on making an appointment. Thank you for your comment.

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.